Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses

Fig. 4

Kaplan–Meier curves for overall survival for axitinib versus everolimus: (a) base-case analysis; (b) sensitivity analysis. aHR, adjusted hazard ratio; CI, confidence interval; ESS, effective sample size; MAIC, matching-adjusted indirect treatment comparison; OS, overall survival

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us